ATE323774T1 - Antitumor-gentherapie bei immuno-und/oder entzündungsmodulation - Google Patents

Antitumor-gentherapie bei immuno-und/oder entzündungsmodulation

Info

Publication number: ATE323774T1
Authority: AT; Austria
Prior art keywords: agent; contg; genome; dna fragment; viral vector
Prior art date: 1993-09-29

Application number

AT01110326T

Other languages

English (en)

Inventor

Bruce Acres

Original Assignee

Transgene Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-29

Filing date

1994-09-28

Publication date

2006-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9451366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE323774(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-09-28 Application filed by Transgene Sa filed Critical Transgene Sa

2006-05-15 Application granted granted Critical

2006-05-15 Publication of ATE323774T1 publication Critical patent/ATE323774T1/de

Links

206010061218 Inflammation Diseases 0.000 title 1
230000000259 anti-tumor effect Effects 0.000 title 1
238000001415 gene therapy Methods 0.000 title 1
230000004054 inflammatory process Effects 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 4
201000011510 cancer Diseases 0.000 abstract 3
210000004027 cell Anatomy 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 3
101150084750 1 gene Proteins 0.000 abstract 2
239000012634 fragment Substances 0.000 abstract 2
239000013603 viral vector Substances 0.000 abstract 2
241000894006 Bacteria Species 0.000 abstract 1
102000019034 Chemokines Human genes 0.000 abstract 1
108010012236 Chemokines Proteins 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 abstract 1
241000700605 Viruses Species 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000002458 infectious effect Effects 0.000 abstract 1
230000028709 inflammatory response Effects 0.000 abstract 1
210000004698 lymphocyte Anatomy 0.000 abstract 1
244000045947 parasite Species 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
231100000617 superantigen Toxicity 0.000 abstract 1
230000010415 tropism Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2033—IL-5
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT01110326T 1993-09-29 1994-09-28 Antitumor-gentherapie bei immuno-und/oder entzündungsmodulation ATE323774T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9311601A FR2710536B1 (fr)	1993-09-29	1993-09-29	Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.

Publications (1)

Publication Number	Publication Date
ATE323774T1 true ATE323774T1 (de)	2006-05-15

Family

ID=9451366

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT94928924T ATE247714T1 (de)	1993-09-29	1994-09-28	Antitumor-gentherapie bei immuno-und/oder entzuendungmodulation
AT01110326T ATE323774T1 (de)	1993-09-29	1994-09-28	Antitumor-gentherapie bei immuno-und/oder entzündungsmodulation

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT94928924T ATE247714T1 (de)	1993-09-29	1994-09-28	Antitumor-gentherapie bei immuno-und/oder entzuendungmodulation

Country Status (12)

Country	Link
EP (2)	EP0721510B1 (de)
JP (1)	JP4094053B2 (de)
AT (2)	ATE247714T1 (de)
AU (1)	AU709336C (de)
DE (2)	DE69434708T2 (de)
DK (2)	DK0721510T3 (de)
ES (2)	ES2260117T3 (de)
FR (1)	FR2710536B1 (de)
HK (1)	HK1042728B (de)
PT (2)	PT721510E (de)
SG (1)	SG96534A1 (de)
WO (1)	WO1995009241A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5833975A (en) *	1989-03-08	1998-11-10	Virogenetics Corporation	Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5662896A (en)	1988-03-21	1997-09-02	Chiron Viagene, Inc.	Compositions and methods for cancer immunotherapy
WO1995031105A1 (en) *	1994-05-13	1995-11-23	Thomas Jefferson University	A method of inducing an immune response using vaccinia virus recombinants
US6093700A (en)	1995-05-11	2000-07-25	Thomas Jefferson University	Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
US6045802A (en) *	1994-10-03	2000-04-04	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) *	1995-07-10	2000-12-26	Therion Biologics Corporation	Generation of immune responses to prostate-specific antigen (PSA)
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
GB2324960A (en) *	1997-05-09	1998-11-11	Univ Manchester	Delivery of naked DNA for wound healing
BR9813930A (pt)	1997-11-06	2006-12-19	Chiron Spa	antìgeno neisserial
ATE446368T1 (de)	1998-01-14	2009-11-15	Novartis Vaccines & Diagnostic	Antigene aus neisseria meningitidis
MX343752B (es)	1998-05-01	2016-11-22	Novartis Vaccines & Diagnostics Inc	Antigenos de neisseria meningitidis y composiciones que los contienen.
NZ571167A (en)	1999-04-30	2010-05-28	Novartis Vaccines & Diagnostic	Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
PT2275551E (pt)	1999-10-29	2015-06-29	Novartis Vaccines & Diagnostic	Péptidos antigénicos de neisseria
ES2588917T3 (es)	2000-01-17	2016-11-07	Glaxosmithkline Biologicals Sa	Vacuna de VME suplementada contra meningococo
US7939087B2 (en)	2000-10-27	2011-05-10	Novartis Vaccines And Diagnostics, Inc.	Nucleic acids and proteins from Streptococcus groups A & B
US20040142885A1 (en) *	2001-01-26	2004-07-22	Stephane Paul	Biological organism for preparing pharmaceutical compositions for treating mammals
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
EP1281767A3 (de)	2001-07-31	2003-05-28	Aladar A. Szalay	Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
ES2386386T3 (es)	2001-12-12	2012-08-20	Novartis Vaccines And Diagnostics S.R.L.	Inmunización contra Chlamydia trachomatis
EP1369491A1 (de)	2002-06-05	2003-12-10	Aladar A. Szalay	Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
ES2369542T3 (es)	2002-07-31	2011-12-01	Seattle Genetics, Inc.	Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
JP4634710B2 (ja) *	2002-07-31	2011-02-16	ゲネルクスコーポレーション	腫瘍の診断および治療のための微生物および細胞
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
MXPA05013879A (es)	2003-06-18	2006-06-27	Genelux Corp	Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
KR101222281B1 (ko)	2004-03-29	2013-01-28	가르파마 컴퍼니 리미티드	신규 갈렉틴 9 개변체 단백질 및 그 용도
EP1933857A2 (de) *	2005-09-07	2008-06-25	Jennerex Biotherapeutics ULC	Systemische behandlung von metastasierten und/oder systemisch dissemierten tumoren mit gm-csf-exprimierenden pockenviren
RU2313349C2 (ru) *	2006-01-16	2007-12-27	Михаил Аркадьевич Шурдов	Способ лечения онкологических заболеваний
DK2054431T3 (da)	2006-06-09	2012-01-02	Novartis Ag	Konformere af bakterielle adhæsiner
EP2415783B1 (de)	2006-10-16	2016-12-14	Genelux Corporation	Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
SG176554A1 (en)	2009-05-12	2012-01-30	Transgene Sa	Method for orthopoxvirus production and purification
AU2010275764A1 (en)	2009-07-21	2012-03-15	Transgene Sa	Enzymatic composition for the digestion of chicken embryos
TWI690322B (zh)	2012-10-02	2020-04-11	法商傳斯堅公司	含病毒的調配物及其使用
US10517943B2 (en)	2014-12-01	2019-12-31	Transgene S.A.	Stable liquid vaccinia virus formulations
CA3062549A1 (en)	2017-05-15	2018-11-22	Janssen Vaccines & Prevention B.V.	Stable virus-containing composition
EP3624851A1 (de)	2017-05-15	2020-03-25	Janssen Vaccines & Prevention B.V.	Stabile virushaltige zusammensetzung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2583429B1 (fr) *	1985-06-18	1989-11-03	Transgene Sa	Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
FR2583770B1 (fr) *	1985-06-21	1988-08-19	Transgene Sa	Expression de l'il-2 humaine dans les cellules de mammiferes par un poxvirus recombine
US5342774A (en) *	1991-05-23	1994-08-30	Ludwig Institute For Cancer Research	Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ATE230615T1 (de) *	1991-10-04	2003-01-15	Whitehead Biomedical Inst	Regulierung der systemischen immunantworten mittels zytokinen und antigenen
EP0668781B1 (de) *	1991-10-25	1999-12-29	Sidney Kimmel Cancer Center	Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
US5314813A (en) *	1992-02-19	1994-05-24	Scripps Research Institute	Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
FR2688514A1 (fr) *	1992-03-16	1993-09-17	Centre Nat Rech Scient	Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994004196A1 (en) *	1992-08-14	1994-03-03	Imperial Cancer Research Technology Limited	Tumour therapy

1993
- 1993-09-29 FR FR9311601A patent/FR2710536B1/fr not_active Expired - Fee Related
1994
- 1994-09-28 DK DK94928924T patent/DK0721510T3/da active
- 1994-09-28 PT PT94928924T patent/PT721510E/pt unknown
- 1994-09-28 DE DE69434708T patent/DE69434708T2/de not_active Expired - Lifetime
- 1994-09-28 ES ES01110326T patent/ES2260117T3/es not_active Expired - Lifetime
- 1994-09-28 DK DK01110326T patent/DK1156119T3/da active
- 1994-09-28 WO PCT/FR1994/001133 patent/WO1995009241A2/fr not_active Ceased
- 1994-09-28 PT PT01110326T patent/PT1156119E/pt unknown
- 1994-09-28 DE DE69433060T patent/DE69433060T2/de not_active Expired - Lifetime
- 1994-09-28 AT AT94928924T patent/ATE247714T1/de active
- 1994-09-28 JP JP51015095A patent/JP4094053B2/ja not_active Expired - Lifetime
- 1994-09-28 EP EP94928924A patent/EP0721510B1/de not_active Expired - Lifetime
- 1994-09-28 EP EP01110326A patent/EP1156119B9/de not_active Expired - Lifetime
- 1994-09-28 AU AU78159/94A patent/AU709336C/en not_active Expired
- 1994-09-28 SG SG9608019A patent/SG96534A1/en unknown
- 1994-09-28 ES ES94928924T patent/ES2204922T3/es not_active Expired - Lifetime
- 1994-09-28 AT AT01110326T patent/ATE323774T1/de active
2002
- 2002-05-21 HK HK02103801.1A patent/HK1042728B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
JPH09502993A (ja)	1997-03-25
DE69434708D1 (de)	2006-05-24
DE69433060T2 (de)	2004-06-03
DK1156119T3 (da)	2006-06-06
EP1156119A3 (de)	2002-10-23
AU7815994A (en)	1995-04-18
AU709336C (en)	2002-06-13
WO1995009241A2 (fr)	1995-04-06
DE69433060D1 (de)	2003-09-25
FR2710536B1 (fr)	1995-12-22
EP1156119B1 (de)	2006-04-19
FR2710536A1 (fr)	1995-04-07
EP1156119A2 (de)	2001-11-21
ES2204922T3 (es)	2004-05-01
EP1156119B9 (de)	2006-08-30
ES2260117T3 (es)	2006-11-01
PT721510E (pt)	2003-11-28
DK0721510T3 (da)	2003-11-17
SG96534A1 (en)	2003-06-16
PT1156119E (pt)	2006-08-31
WO1995009241A3 (fr)	1995-06-22
EP0721510A1 (de)	1996-07-17
DE69434708T2 (de)	2007-04-05
AU709336B2 (en)	1999-08-26
ATE247714T1 (de)	2003-09-15
EP0721510B1 (de)	2003-08-20
HK1042728A1 (en)	2002-08-23
HK1042728B (zh)	2006-11-24
JP4094053B2 (ja)	2008-06-04

Legal Events

Date

Code

Title

Description

2007-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1156119

Country of ref document: EP

Publication	Publication Date	Title
AU709336C (en)	2002-06-13	Anticancer gene therapy by modulation of immune and/or inflammatory response
GR3032660T3 (en)	2000-06-30	Lymphokine gene therapy of cancer.
Thompson et al.	1986	Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Saito et al.	1982	Induction of interferon-γ in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes
DE69233186D1 (de)	2003-10-09	Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
ZA886471B (en)	1989-04-26	Conjugates of cytokines with imunologulins
Saito et al.	1984	Activated macrophages are responsible for the tumor‐inhibitory effect in mice receiving intravenous injection of OK‐432
DE3684732D1 (de)	1992-05-14	Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
CA2282300A1 (en)	1998-08-27	Recombinant pox virus for immunization against muc1 tumor-associated antigen
ZA875681B (en)	1988-04-27	Recombinant vaccine
AU7679787A (en)	1988-02-18	Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
Ratliff et al.	1981	Interferon induction and augmentation of natural-killer activity by Staphylococcus protein A
Ju et al.	1998	Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity
Wilczyńska et al.	2001	Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer.
NO930798L (no)	1993-09-06	Fremgangsmaate og middel mot tumorer
EP0662150A4 (de)	1997-01-29	Maspin- ein neues serpin mit tumor unterdrückender aktivität.
Crusinberry et al.	1991	Immunotherapy of renal cell cancer
Lu et al.	2002	Specific immunotherapy against occult cancer metastases
Kasaoka et al.	2000	Gene Therapy for Murine Renal Cell Carcinoma Using Genetically Engineered Tumor Cells to Secrete lnterleukin-12
Factor-o	1993	Resistance of Spontaneously Transformed Syrian Hamster Embryo Cells and Their Malignant Variants to Cytotoxic Activity of
Sikora	1994	First 5 years of gene therapy for cancer.
Mukai et al.	1996	Efficacy of in vitro sensitized cells generated by in vivo priming with OK-432 for adoptive immunotherapy of the poorly immunogenic B 16-BL6 melanoma
Capone	1984	PASSIVE IMMUNOTHERAPY OF HUMAN BREAST TUMORS WITH MONOCLONAL ANTIBODIES.
Connor et al.	2003	298. Treatment of Subcutaneous Melanoma after Vaccination with Cells Expressing Xenoepitopes in the α (1, 3) Galactosiltransferase (αGT) Knockout Mouse Model
Iwaguchi et al.	1990	Hyperthermia and Immune Response